Jasper Historical Income Statement

JSPR Stock

USD 22.81 0.43 1.85%

Historical analysis of Jasper Therapeutics income statement accounts such as Selling General Administrative of 11.2 M or Other Operating Expenses of 40 M can show how well Jasper Therapeutics performed in making a profits. Evaluating Jasper Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Jasper Therapeutics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Jasper Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Jasper Therapeutics is a good buy for the upcoming year.

Net Income Gross Profit

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Jasper Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

To learn how to invest in Jasper Stock, please use our How to Invest in Jasper Therapeutics guide.

About Jasper Income Statement Analysis

Jasper Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Jasper Therapeutics shareholders. The income statement also shows Jasper investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Jasper Therapeutics Income Statement Chart

As of 12/01/2024, Depreciation And Amortization is likely to grow to about 1.2 M, while Interest Expense is likely to drop slightly above 8.4 M.

Selling General Administrative Other Operating Expenses Research Development Total Operating Expenses

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Jasper Therapeutics. It is also known as Jasper Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most accounts from Jasper Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Jasper Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Jasper Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

To learn how to invest in Jasper Stock, please use our How to Invest in Jasper Therapeutics guide.As of 12/01/2024, Depreciation And Amortization is likely to grow to about 1.2 M, while Interest Expense is likely to drop slightly above 8.4 M.

	2010	2023	2024 (projected)
Interest Income	701K	5.2M	3.2M
Net Interest Income	701K	5.2M	3.2M

Interest Income Net Interest Income

Jasper Therapeutics income statement Correlations

	Depreciation And Amortization	Selling General Administrative	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Gross Profit	Net Income From Continuing Ops	Cost Of Revenue	Non Operating Income Net Other	Net Interest Income	Interest Income	Selling And Marketing Expenses
Depreciation And Amortization		-0.83	-0.83	0.82	0.86	-0.82	0.88	-0.83	0.86	-0.18	0.81	0.55	0.71	0.73	-0.71	-0.46	-0.46	-0.46	0.45
Selling General Administrative	-0.83		0.99	-0.95	-0.91	0.98	-0.91	0.99	-0.9	0.62	-0.83	-0.74	-0.95	-0.95	0.97	0.65	0.65	0.65	-0.53
Other Operating Expenses	-0.83	0.99		-0.97	-0.94	1.0	-0.94	1.0	-0.94	0.52	-0.88	-0.63	-0.93	-0.95	0.95	0.75	0.75	0.75	-0.58
Operating Income	0.82	-0.95	-0.97		0.98	-0.96	0.98	-0.97	0.98	-0.49	0.94	0.56	0.96	0.98	-0.93	-0.78	-0.78	-0.78	0.75
Ebit	0.86	-0.91	-0.94	0.98		-0.95	1.0	-0.94	1.0	-0.32	0.98	0.45	0.89	0.94	-0.86	-0.81	-0.81	-0.81	0.78
Research Development	-0.82	0.98	1.0	-0.96	-0.95		-0.95	1.0	-0.94	0.48	-0.9	-0.59	-0.91	-0.94	0.93	0.78	0.78	0.78	-0.59
Ebitda	0.88	-0.91	-0.94	0.98	1.0	-0.95		-0.94	1.0	-0.31	0.98	0.46	0.89	0.93	-0.86	-0.79	-0.79	-0.79	0.76
Total Operating Expenses	-0.83	0.99	1.0	-0.97	-0.94	1.0	-0.94		-0.94	0.52	-0.88	-0.63	-0.93	-0.95	0.95	0.75	0.75	0.75	-0.58
Income Before Tax	0.86	-0.9	-0.94	0.98	1.0	-0.94	1.0	-0.94		-0.31	0.99	0.43	0.89	0.94	-0.85	-0.82	-0.82	-0.82	0.79
Total Other Income Expense Net	-0.18	0.62	0.52	-0.49	-0.32	0.48	-0.31	0.52	-0.31		-0.18	-0.82	-0.69	-0.61	0.73	0.15	0.15	0.15	-0.14
Net Income	0.81	-0.83	-0.88	0.94	0.98	-0.9	0.98	-0.88	0.99	-0.18		0.27	0.81	0.89	-0.77	-0.87	-0.87	-0.87	0.84
Income Tax Expense	0.55	-0.74	-0.63	0.56	0.45	-0.59	0.46	-0.63	0.43	-0.82	0.27		0.72	0.6	-0.78	-0.01	-0.01	-0.01	0.01
Gross Profit	0.71	-0.95	-0.93	0.96	0.89	-0.91	0.89	-0.93	0.89	-0.69	0.81	0.72		0.98	-0.99	-0.66	-0.67	-0.67	0.67
Net Income From Continuing Ops	0.73	-0.95	-0.95	0.98	0.94	-0.94	0.93	-0.95	0.94	-0.61	0.89	0.6	0.98		-0.96	-0.77	-0.77	-0.77	0.74
Cost Of Revenue	-0.71	0.97	0.95	-0.93	-0.86	0.93	-0.86	0.95	-0.85	0.73	-0.77	-0.78	-0.99	-0.96		0.63	0.63	0.63	-0.55
Non Operating Income Net Other	-0.46	0.65	0.75	-0.78	-0.81	0.78	-0.79	0.75	-0.82	0.15	-0.87	-0.01	-0.66	-0.77	0.63		1.0	1.0	-0.8
Net Interest Income	-0.46	0.65	0.75	-0.78	-0.81	0.78	-0.79	0.75	-0.82	0.15	-0.87	-0.01	-0.67	-0.77	0.63	1.0		1.0	-0.81
Interest Income	-0.46	0.65	0.75	-0.78	-0.81	0.78	-0.79	0.75	-0.82	0.15	-0.87	-0.01	-0.67	-0.77	0.63	1.0	1.0		-0.81
Selling And Marketing Expenses	0.45	-0.53	-0.58	0.75	0.78	-0.59	0.76	-0.58	0.79	-0.14	0.84	0.01	0.67	0.74	-0.55	-0.8	-0.81	-0.81

Click cells to compare fundamentals

Jasper Therapeutics Account Relationship Matchups

Pair Trading with Jasper Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Jasper Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Jasper Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Jasper Stock

0.56	HCM	HUTCHMED DRC	Pair Corr
0.47	ZTS	Zoetis Inc	Pair Corr
0.4	LLY	Eli Lilly	Pair Corr
0.39	RDY	Dr Reddys Laboratories	Pair Corr
0.37	PFE	Pfizer Inc Aggressive Push	Pair Corr

The ability to find closely correlated positions to Jasper Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Jasper Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Jasper Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Jasper Therapeutics to buy it.

The correlation of Jasper Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Jasper Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Jasper Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Jasper Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Jasper Stock Analysis

When running Jasper Therapeutics' price analysis, check to measure Jasper Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jasper Therapeutics is operating at the current time. Most of Jasper Therapeutics' value examination focuses on studying past and present price action to predict the probability of Jasper Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jasper Therapeutics' price. Additionally, you may evaluate how the addition of Jasper Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Jasper Historical Income Statement

About Jasper Income Statement Analysis

Jasper Therapeutics Income Statement Chart

Other Operating Expenses

Total Operating Expenses

Jasper Therapeutics income statement Correlations

Jasper Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Pair Trading with Jasper Therapeutics

Moving against Jasper Stock

Additional Tools for Jasper Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Depreciation And Amortization	Interest Expense
Selling General Administrative	Other Operating Expenses
Operating Income	Ebit
Research Development	Ebitda
Total Operating Expenses	Income Before Tax
Total Other Income Expense Net	Net Income Applicable To Common Shares
Net Income	Income Tax Expense
Total Revenue	Gross Profit
Net Income From Continuing Ops	Cost Of Revenue
Reconciled Depreciation	Non Operating Income Net Other
Net Interest Income	Interest Income
Selling And Marketing Expenses

Research Development	+ 1.0	Other Operating Expenses
Total Operating Expenses	+ 1.0	Other Operating Expenses
Ebitda	+ 1.0	Ebit
Income Before Tax	+ 1.0	Ebit
Total Operating Expenses	+ 1.0	Research Development
Income Before Tax	+ 1.0	Ebitda

Cost Of Revenue	- 0.99	Gross Profit
Total Operating Expenses	- 0.97	Operating Income
Operating Income	- 0.97	Other Operating Expenses
Cost Of Revenue	- 0.96	Net Income From Continuing Ops
Research Development	- 0.96	Operating Income
Net Income From Continuing Ops	- 0.95	Total Operating Expenses